25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

COSMO Pharmaceuticals SA
Buy, Hold or Sell?

Let's analyze COSMO Pharmaceuticals SA together

I guess you are interested in COSMO Pharmaceuticals SA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of COSMO Pharmaceuticals SA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about COSMO Pharmaceuticals SA

I send you an email if I find something interesting about COSMO Pharmaceuticals SA.

1. Quick Overview

1.1. Quick analysis of COSMO Pharmaceuticals SA (30 sec.)










1.2. What can you expect buying and holding a share of COSMO Pharmaceuticals SA? (30 sec.)

How much money do you get?

How much money do you get?
£5.25
When do you have the money?
1 year
How often do you get paid?
50.0%

What is your share worth?

Current worth
£26.64
Expected worth in 1 year
£20.25
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
£-2.19
Return On Investment
-3.4%

For what price can you sell your share?

Current Price per Share
£63.66
Expected price per share
£63.20 - £74.30
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of COSMO Pharmaceuticals SA (5 min.)




Live pricePrice per Share (EOD)
£63.66
Intrinsic Value Per Share
£2.77 - £20.96
Total Value Per Share
£29.41 - £47.60

2.2. Growth of COSMO Pharmaceuticals SA (5 min.)




Is COSMO Pharmaceuticals SA growing?

Current yearPrevious yearGrowGrow %
How rich?$536.8m$580.3m-$43.4m-8.1%

How much money is COSMO Pharmaceuticals SA making?

Current yearPrevious yearGrowGrow %
Making money-$6.1m$21.5m-$27.7m-449.2%
Net Profit Margin-5.3%16.9%--

How much money comes from the company's main activities?

2.3. Financial Health of COSMO Pharmaceuticals SA (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of COSMO Pharmaceuticals SA?

Welcome investor! COSMO Pharmaceuticals SA's management wants to use your money to grow the business. In return you get a share of COSMO Pharmaceuticals SA.

First you should know what it really means to hold a share of COSMO Pharmaceuticals SA. And how you can make/lose money.

Speculation

The Price per Share of COSMO Pharmaceuticals SA is £63.66. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of COSMO Pharmaceuticals SA.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in COSMO Pharmaceuticals SA, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is £26.64. Based on the TTM, the Book Value Change Per Share is £-1.60 per quarter. Based on the YOY, the Book Value Change Per Share is £-2.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is £1.05 per quarter.
Based on historical numbers we can estimate the returns while holding a share of COSMO Pharmaceuticals SA.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 £% of Price per Share£% of Price per Share£% of Price per Share£% of Price per Share£% of Price per Share
Usd Eps-0.38-0.6%-0.38-0.6%1.312.1%-0.03-0.1%2.433.8%
Usd Book Value Change Per Share-2.00-3.1%-2.00-3.1%-2.62-4.1%-0.75-1.2%1.502.4%
Usd Dividend Per Share1.312.1%1.312.1%1.181.8%0.500.8%0.661.0%
Usd Total Gains Per Share-0.69-1.1%-0.69-1.1%-1.44-2.3%-0.25-0.4%2.163.4%
Usd Price Per Share64.20-64.20-77.18-85.05-71.60-
Price to Earnings Ratio-167.52--167.52-58.82--53.12--41.96-
Price-to-Total Gains Ratio-93.68--93.68--53.54-9.38-14.92-
Price to Book Ratio1.93-1.93-2.18-2.47-2.09-
Price-to-Total Gains Ratio-93.68--93.68--53.54-9.38-14.92-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share79.66562568
Number of shares12
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share1.310.50
Usd Book Value Change Per Share-2.00-0.75
Usd Total Gains Per Share-0.69-0.25
Gains per Quarter (12 shares)-8.22-3.05
Gains per Year (12 shares)-32.89-12.22
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
163-96-4324-36-22
2126-192-7648-72-34
3189-288-10972-108-46
4252-384-14296-144-58
5315-479-175119-181-70
6378-575-208143-217-82
7441-671-241167-253-94
8504-767-274191-289-106
9567-863-307215-325-118
10630-959-340239-361-130

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%2.01.00.066.7%2.03.00.040.0%5.05.00.050.0%13.07.00.065.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%13.07.00.065.0%
Dividend per Share1.00.00.0100.0%2.00.01.066.7%2.00.03.040.0%5.00.05.050.0%6.00.014.030.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%13.07.00.065.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of COSMO Pharmaceuticals SA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.596-1.5960%-2.093+31%-0.601-62%1.196-233%
Book Value Per Share--26.64026.6400%28.236-6%27.624-4%25.365+5%
Current Ratio--3.9753.9750%1.570+153%9.878-60%10.060-60%
Debt To Asset Ratio--0.2260.2260%0.389-42%0.327-31%0.245-8%
Debt To Equity Ratio--0.2960.2960%0.647-54%0.500-41%0.360-18%
Dividend Per Share--1.0491.0490%0.941+11%0.398+164%0.527+99%
Enterprise Value--751523963.800751523963.8000%958244368.047-22%1052067966.927-29%1290625644.889-42%
Eps---0.306-0.3060%1.049-129%-0.026-92%1.938-116%
Ev To Ebitda Ratio--38.15038.1500%20.179+89%14.675+160%-20.472+154%
Ev To Sales Ratio--8.1008.1000%9.386-14%14.833-45%19.706-59%
Free Cash Flow Per Share--1.1371.1370%1.730-34%0.205+454%-0.014+101%
Free Cash Flow To Equity Per Share---11.981-11.9810%-1.050-91%-3.915-67%-1.300-89%
Gross Profit Margin--1.1221.1220%0.976+15%1.068+5%1.115+1%
Intrinsic Value_10Y_max--20.957--------
Intrinsic Value_10Y_min--2.771--------
Intrinsic Value_1Y_max--1.269--------
Intrinsic Value_1Y_min--0.060--------
Intrinsic Value_3Y_max--4.446--------
Intrinsic Value_3Y_min--0.370--------
Intrinsic Value_5Y_max--8.387--------
Intrinsic Value_5Y_min--0.885--------
Market Cap955051688.520+13%826192963.800826192963.8000%1013095368.047-18%1073387766.927-23%885257238.762-7%
Net Profit Margin---0.053-0.0530%0.169-132%-0.015-73%0.447-112%
Operating Margin--0.0660.0660%0.329-80%0.146-55%0.491-86%
Operating Ratio--0.9340.9340%0.725+29%0.914+2%0.940-1%
Pb Ratio2.390+19%1.9261.9260%2.184-12%2.473-22%2.090-8%
Pe Ratio-207.882-24%-167.517-167.5170%58.815-385%-53.121-68%-41.962-75%
Price Per Share63.661+19%51.30051.3000%61.679-17%67.965-25%57.215-10%
Price To Free Cash Flow Ratio55.989+19%45.11845.1180%35.643+27%115.527-61%42.937+5%
Price To Total Gains Ratio-116.259-24%-93.685-93.6850%-53.543-43%9.381-1099%14.923-728%
Quick Ratio--3.0623.0620%1.717+78%11.618-74%12.263-75%
Return On Assets---0.009-0.0090%0.023-139%-0.003-68%0.083-111%
Return On Equity---0.012-0.0120%0.038-131%-0.003-78%0.102-111%
Total Gains Per Share---0.548-0.5480%-1.152+110%-0.203-63%1.724-132%
Usd Book Value--536895650.400536895650.4000%580384303.200-7%550455820.800-2%492137050.913+9%
Usd Book Value Change Per Share---1.998-1.9980%-2.619+31%-0.752-62%1.497-233%
Usd Book Value Per Share--33.33733.3370%35.335-6%34.569-4%31.742+5%
Usd Dividend Per Share--1.3121.3120%1.177+11%0.498+164%0.660+99%
Usd Enterprise Value--940457088.299940457088.2990%1199147002.174-22%1316557853.813-29%1615088932.014-42%
Usd Eps---0.383-0.3830%1.312-129%-0.032-92%2.425-116%
Usd Free Cash Flow--22915636.80022915636.8000%35569532.057-36%4901180.931+368%252878.532+8962%
Usd Free Cash Flow Per Share--1.4231.4230%2.166-34%0.257+454%-0.018+101%
Usd Free Cash Flow To Equity Per Share---14.993-14.9930%-1.314-91%-4.899-67%-1.627-89%
Usd Market Cap1195151683.014+13%1033897874.8991033897874.8990%1267787543.574-18%1343237451.533-23%1107810908.587-7%
Usd Price Per Share79.666+19%64.19764.1970%77.185-17%85.051-25%71.599-10%
Usd Profit---6171904.800-6171904.8000%21555365.000-129%392939.600-1671%36814335.966-117%
Usd Revenue--116104892.000116104892.0000%127754174.600-9%95954098.360+21%87696203.940+32%
Usd Total Gains Per Share---0.685-0.6850%-1.442+110%-0.255-63%2.157-132%
 EOD+4 -4MRQTTM+0 -0YOY+15 -255Y+14 -2610Y+17 -23

3.3 Fundamental Score

Let's check the fundamental score of COSMO Pharmaceuticals SA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-207.882
Price to Book Ratio (EOD)Between0-12.390
Net Profit Margin (MRQ)Greater than0-0.053
Operating Margin (MRQ)Greater than00.066
Quick Ratio (MRQ)Greater than13.062
Current Ratio (MRQ)Greater than13.975
Debt to Asset Ratio (MRQ)Less than10.226
Debt to Equity Ratio (MRQ)Less than10.296
Return on Equity (MRQ)Greater than0.15-0.012
Return on Assets (MRQ)Greater than0.05-0.009
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of COSMO Pharmaceuticals SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.553
Ma 20Greater thanMa 5060.981
Ma 50Greater thanMa 10064.211
Ma 100Greater thanMa 20070.760
OpenGreater thanClose63.200
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About COSMO Pharmaceuticals SA

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, a submucosal injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin SV MMX " IBS-D, a formulation that is in Phase III clinical trial to treat colonic infections and irritable bowel syndrome with diarrhoea; CB-03-10, an oral androgen receptor antagonist, which is in Phase I clinical trial for treatment solid tumors; CB-01-33 that is in preclinical studies for the treatment of bile acid diarrhea; and CB-01-35, an enema solution, which is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, RedHill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Fundamental data was last updated by Penke on 2025-01-02 08:22:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is fair priced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit COSMO Pharmaceuticals SA earns for each £1 of revenue.

  • Above 10% is considered healthy but always compare COSMO Pharmaceuticals SA to the  industry mean.
  • A Net Profit Margin of -5.3% means that £-0.05 for each £1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of COSMO Pharmaceuticals SA:

  • The MRQ is -5.3%. The company is making a loss. -1
  • The TTM is -5.3%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-5.3%TTM-5.3%0.0%
TTM-5.3%YOY16.9%-22.2%
TTM-5.3%5Y-1.5%-3.9%
5Y-1.5%10Y44.7%-46.2%
4.3.1.2. Return on Assets

Shows how efficient COSMO Pharmaceuticals SA is using its assets to generate profit.

  • Above 5% is considered healthy but always compare COSMO Pharmaceuticals SA to the  industry mean.
  • -0.9% Return on Assets means that COSMO Pharmaceuticals SA generated £-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of COSMO Pharmaceuticals SA:

  • The MRQ is -0.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -0.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.9%TTM-0.9%0.0%
TTM-0.9%YOY2.3%-3.2%
TTM-0.9%5Y-0.3%-0.6%
5Y-0.3%10Y8.3%-8.6%
4.3.1.3. Return on Equity

Shows how efficient COSMO Pharmaceuticals SA is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare COSMO Pharmaceuticals SA to the  industry mean.
  • -1.2% Return on Equity means COSMO Pharmaceuticals SA generated £-0.01 for each £1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of COSMO Pharmaceuticals SA:

  • The MRQ is -1.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -1.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.2%TTM-1.2%0.0%
TTM-1.2%YOY3.8%-4.9%
TTM-1.2%5Y-0.3%-0.9%
5Y-0.3%10Y10.2%-10.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of COSMO Pharmaceuticals SA.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient COSMO Pharmaceuticals SA is operating .

  • Measures how much profit COSMO Pharmaceuticals SA makes for each £1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare COSMO Pharmaceuticals SA to the  industry mean.
  • An Operating Margin of 6.6% means the company generated £0.07  for each £1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of COSMO Pharmaceuticals SA:

  • The MRQ is 6.6%. The company is operating less efficient.
  • The TTM is 6.6%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ6.6%TTM6.6%0.0%
TTM6.6%YOY32.9%-26.3%
TTM6.6%5Y14.6%-8.0%
5Y14.6%10Y49.1%-34.5%
4.3.2.2. Operating Ratio

Measures how efficient COSMO Pharmaceuticals SA is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 0.93 means that the operating costs are £0.93 for each £1 in net sales.

Let's take a look of the Operating Ratio trends of COSMO Pharmaceuticals SA:

  • The MRQ is 0.934. The company is less efficient in keeping operating costs low.
  • The TTM is 0.934. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.934TTM0.9340.000
TTM0.934YOY0.725+0.209
TTM0.9345Y0.914+0.019
5Y0.91410Y0.940-0.026
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of COSMO Pharmaceuticals SA.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if COSMO Pharmaceuticals SA is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 3.98 means the company has £3.98 in assets for each £1 in short-term debts.

Let's take a look of the Current Ratio trends of COSMO Pharmaceuticals SA:

  • The MRQ is 3.975. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.975. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.975TTM3.9750.000
TTM3.975YOY1.570+2.405
TTM3.9755Y9.878-5.903
5Y9.87810Y10.060-0.181
4.4.3.2. Quick Ratio

Measures if COSMO Pharmaceuticals SA is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare COSMO Pharmaceuticals SA to the  industry mean.
  • A Quick Ratio of 3.06 means the company can pay off £3.06 for each £1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of COSMO Pharmaceuticals SA:

  • The MRQ is 3.062. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.062. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.062TTM3.0620.000
TTM3.062YOY1.717+1.345
TTM3.0625Y11.618-8.556
5Y11.61810Y12.263-0.645
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of COSMO Pharmaceuticals SA.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of COSMO Pharmaceuticals SA assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare COSMO Pharmaceuticals SA to industry mean.
  • A Debt to Asset Ratio of 0.23 means that COSMO Pharmaceuticals SA assets are financed with 22.6% credit (debt) and the remaining percentage (100% - 22.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of COSMO Pharmaceuticals SA:

  • The MRQ is 0.226. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.226. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.226TTM0.2260.000
TTM0.226YOY0.389-0.164
TTM0.2265Y0.327-0.101
5Y0.32710Y0.245+0.082
4.5.4.2. Debt to Equity Ratio

Measures if COSMO Pharmaceuticals SA is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare COSMO Pharmaceuticals SA to the  industry mean.
  • A Debt to Equity ratio of 29.6% means that company has £0.30 debt for each £1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of COSMO Pharmaceuticals SA:

  • The MRQ is 0.296. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.296. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.296TTM0.2960.000
TTM0.296YOY0.647-0.351
TTM0.2965Y0.500-0.204
5Y0.50010Y0.360+0.140
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every £1 in earnings COSMO Pharmaceuticals SA generates.

  • Above 15 is considered overpriced but always compare COSMO Pharmaceuticals SA to the  industry mean.
  • A PE ratio of -167.52 means the investor is paying £-167.52 for every £1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of COSMO Pharmaceuticals SA:

  • The EOD is -207.882. Based on the earnings, the company is expensive. -2
  • The MRQ is -167.517. Based on the earnings, the company is expensive. -2
  • The TTM is -167.517. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-207.882MRQ-167.517-40.365
MRQ-167.517TTM-167.5170.000
TTM-167.517YOY58.815-226.332
TTM-167.5175Y-53.121-114.396
5Y-53.12110Y-41.962-11.159
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of COSMO Pharmaceuticals SA:

  • The EOD is 55.989. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 45.118. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 45.118. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD55.989MRQ45.118+10.871
MRQ45.118TTM45.1180.000
TTM45.118YOY35.643+9.475
TTM45.1185Y115.527-70.409
5Y115.52710Y42.937+72.590
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of COSMO Pharmaceuticals SA is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of 1.93 means the investor is paying £1.93 for each £1 in book value.

Let's take a look of the Price to Book Ratio trends of COSMO Pharmaceuticals SA:

  • The EOD is 2.390. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.926. Based on the equity, the company is underpriced. +1
  • The TTM is 1.926. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.390MRQ1.926+0.464
MRQ1.926TTM1.9260.000
TTM1.926YOY2.184-0.259
TTM1.9265Y2.473-0.548
5Y2.47310Y2.090+0.383
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
Total Assets553,980
Total Liabilities124,944
Total Stockholder Equity422,160
 As reported
Total Liabilities 124,944
Total Stockholder Equity+ 422,160
Total Assets = 553,980

Assets

Total Assets553,980
Total Current Assets102,226
Long-term Assets451,754
Total Current Assets
Cash And Cash Equivalents 50,275
Net Receivables 28,454
Inventory 14,198
Other Current Assets 9,299
Total Current Assets  (as reported)102,226
Total Current Assets  (calculated)102,226
+/-0
Long-term Assets
Property Plant Equipment 28,588
Goodwill 24,005
Intangible Assets 355,624
Long-term Assets Other 40,251
Long-term Assets  (as reported)451,754
Long-term Assets  (calculated)448,468
+/- 3,286

Liabilities & Shareholders' Equity

Total Current Liabilities25,714
Long-term Liabilities99,230
Total Stockholder Equity422,160
Total Current Liabilities
Short-term Debt 897
Accounts payable 8,783
Other Current Liabilities 4,050
Total Current Liabilities  (as reported)25,714
Total Current Liabilities  (calculated)13,730
+/- 11,984
Long-term Liabilities
Long-term Liabilities  (as reported)99,230
Long-term Liabilities  (calculated)0
+/- 99,230
Total Stockholder Equity
Common Stock4,562
Retained Earnings 296,521
Accumulated Other Comprehensive Income -21,181
Other Stockholders Equity 142,258
Total Stockholder Equity (as reported)422,160
Total Stockholder Equity (calculated)422,160
+/-0
Other
Cash and Short Term Investments 50,275
Common Stock Shares Outstanding 16,105
Current Deferred Revenue9,303
Liabilities and Stockholders Equity 553,980
Net Debt -48,436
Short Long Term Debt Total 1,839



6.2. Balance Sheets Structured

All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-31
> Total Assets 
23,463
28,212
23,610
47,228
57,765
71,464
91,825
78,038
151,845
243,004
225,621
437,943
443,474
497,974
625,686
585,160
596,161
805,562
759,592
553,980
553,980759,592805,562596,161585,160625,686497,974443,474437,943225,621243,004151,84578,03891,82571,46457,76547,22823,61028,21223,463
   > Total Current Assets 
4,142
8,305
9,984
33,666
33,693
29,826
43,440
28,597
39,980
188,331
70,709
137,930
187,074
197,306
374,167
302,365
252,868
275,849
306,097
102,226
102,226306,097275,849252,868302,365374,167197,306187,074137,93070,709188,33139,98028,59743,44029,82633,69333,6669,9848,3054,142
       Cash And Cash Equivalents 
274
683
1,119
25,505
22,166
17,161
28,351
13,624
27,302
46,338
34,138
71,276
117,649
144,944
210,689
110,387
185,937
198,560
185,825
50,275
50,275185,825198,560185,937110,387210,689144,944117,64971,27634,13846,33827,30213,62428,35117,16122,16625,5051,119683274
       Short-term Investments 
0
0
0
0
0
139
101
0
0
121,823
25,326
45,063
48,836
27,759
138,747
157,822
26,915
23,647
55,128
0
055,12823,64726,915157,822138,74727,75948,83645,06325,326121,8230010113900000
       Net Receivables 
0
0
-370
0
578
0
0
0
6,235
11,619
4,796
16,805
14,968
13,190
12,762
19,075
26,990
24,451
38,612
28,454
28,45438,61224,45126,99019,07512,76213,19014,96816,8054,79611,6196,2350005780-37000
       Inventory 
1,021
1,306
966
1,549
1,507
1,515
1,299
1,838
2,192
2,859
3,326
2,247
2,304
3,241
3,937
6,143
5,707
13,119
11,498
14,198
14,19811,49813,1195,7076,1433,9373,2412,3042,2473,3262,8592,1921,8381,2991,5151,5071,5499661,3061,021
       Other Current Assets 
2,847
6,316
8,269
6,612
9,442
11,011
13,689
13,135
10,486
5,692
3,123
2,539
3,317
8,172
8,032
8,938
7,319
16,072
15,034
9,299
9,29915,03416,0727,3198,9388,0328,1723,3172,5393,1235,69210,48613,13513,68911,0119,4426,6128,2696,3162,847
   > Long-term Assets 
19,321
19,907
13,626
13,562
24,072
41,638
48,385
49,441
111,865
54,673
154,912
300,013
256,400
300,668
251,519
282,795
343,293
529,713
453,495
451,754
451,754453,495529,713343,293282,795251,519300,668256,400300,013154,91254,673111,86549,44148,38541,63824,07213,56213,62619,90719,321
       Property Plant Equipment 
9,559
12,952
7,096
6,891
6,986
6,810
6,444
6,001
22,228
21,704
21,445
21,130
20,672
30,152
28,616
30,187
29,302
30,478
30,277
28,588
28,58830,27730,47829,30230,18728,61630,15220,67221,13021,44521,70422,2286,0016,4446,8106,9866,8917,09612,9529,559
       Goodwill 
109
109
109
109
109
109
109
109
109
109
109
109
109
109
1,439
1,439
1,439
24,005
24,005
24,005
24,00524,00524,0051,4391,4391,439109109109109109109109109109109109109109109
       Intangible Assets 
950
928
3,384
3,175
6,856
12,035
20,387
21,969
22,152
16,346
10,305
4,496
19,546
28,525
35,524
49,217
26,640
372,733
366,838
355,624
355,624366,838372,73326,64049,21735,52428,52519,5464,49610,30516,34622,15221,96920,38712,0356,8563,1753,384928950
       Long-term Assets Other 
8,039
4,394
1,906
1,953
6,769
2,335
2,318
20,555
0
121,823
25,326
45,063
48,836
29,632
140,706
170,310
54,021
58,431
64,550
40,251
40,25164,55058,43154,021170,310140,70629,63248,83645,06325,326121,823020,5552,3182,3356,7691,9531,9064,3948,039
> Total Liabilities 
24,343
27,581
18,266
12,081
14,529
11,669
33,459
14,604
27,244
22,849
73,332
34,296
27,916
27,857
180,832
191,427
196,036
292,884
295,804
124,944
124,944295,804292,884196,036191,427180,83227,85727,91634,29673,33222,84927,24414,60433,45911,66914,52912,08118,26627,58124,343
   > Total Current Liabilities 
7,748
12,147
11,558
6,578
9,384
7,288
27,211
10,309
12,379
9,699
60,656
25,042
18,717
19,432
15,345
15,705
21,793
21,236
194,946
25,714
25,714194,94621,23621,79315,70515,34519,43218,71725,04260,6569,69912,37910,30927,2117,2889,3846,57811,55812,1477,748
       Short-term Debt 
4,088
7,662
4,576
1,540
1,391
1,334
1,321
892
1,797
1,986
2,000
1,555
849
649
527
1,500
2,936
889
171,827
897
897171,8278892,9361,5005276498491,5552,0001,9861,7978921,3211,3341,3911,5404,5767,6624,088
       Accounts payable 
3,113
3,400
7,765
705
4,228
4,113
5,603
4,138
4,010
4,157
5,466
4,281
4,192
7,640
4,390
4,298
2,623
4,102
7,588
8,783
8,7837,5884,1022,6234,2984,3907,6404,1924,2815,4664,1574,0104,1385,6034,1134,2287057,7653,4003,113
       Other Current Liabilities 
233
547
888
4,162
3,203
1,301
20,018
4,874
1,295
-868
-27,580
17,795
10,894
9,597
9,999
9,407
13,428
12,649
12,795
4,050
4,05012,79512,64913,4289,4079,9999,59710,89417,795-27,580-8681,2954,87420,0181,3013,2034,162888547233
   > Long-term Liabilities 
16,595
15,434
6,708
5,503
5,145
4,381
6,248
4,295
14,865
13,150
12,676
9,254
9,199
8,425
165,487
175,722
174,243
271,648
100,858
99,230
99,230100,858271,648174,243175,722165,4878,4259,1999,25412,67613,15014,8654,2956,2484,3815,1455,5036,70815,43416,595
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
4,598
7,864
12,385
9,035
102,620
0
0
00102,6209,03512,3857,8644,5980000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
14,705
21,563
27,551
23,397
245,559
0
0
00245,55923,39727,55121,56314,7050000000000000
> Total Stockholder Equity
-880
631
5,344
35,147
43,236
59,795
58,065
63,190
124,391
220,140
152,276
403,635
415,546
470,117
443,760
393,733
400,125
505,276
456,927
422,160
422,160456,927505,276400,125393,733443,760470,117415,546403,635152,276220,140124,39163,19058,06559,79543,23635,1475,344631-880
   Common Stock
2,300
2,550
2,550
3,469
3,469
3,469
3,749
3,749
3,749
3,749
3,749
3,749
3,749
3,910
3,910
3,910
3,910
4,562
4,562
4,562
4,5624,5624,5623,9103,9103,9103,9103,7493,7493,7493,7493,7493,7493,7493,4693,4693,4692,5502,5502,300
   Retained Earnings 
-3,905
-4,656
-4,573
116
116
9,517
17,174
17,212
35,985
107,635
126,984
372,942
372,562
319,620
300,016
272,432
265,350
293,311
262,243
296,521
296,521262,243293,311265,350272,432300,016319,620372,562372,942126,984107,63535,98517,21217,1749,517116116-4,573-4,656-3,905
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
84,448
84,448
84,448
84,448
0
0
0
00084,44884,44884,44884,4480000000000000
   Treasury Stock000-49,400-43,686-18,3530-28,073000000000000
   Other Stockholders Equity 
725
2,737
7,367
31,678
39,651
42,759
40,749
34,548
84,533
45,506
21,543
-28,073
-28,073
84,448
66,095
40,762
35,048
141,108
130,785
142,258
142,258130,785141,10835,04840,76266,09584,448-28,073-28,07321,54345,50684,53334,54840,74942,75939,65131,6787,3672,737725



6.3. Balance Sheets

All numbers in thousands.




6.4. Cash Flows

All numbers in thousands.




6.5. Income Statements

All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. All numbers in thousands.

Gross Profit (+$)
totalRevenue92,780
Cost of Revenue-39,340
Gross Profit53,44053,440
 
Operating Income (+$)
Gross Profit53,440
Operating Expense-47,294
Operating Income6,1466,146
 
Operating Expense (+$)
Research Development18,811
Selling General Administrative4,801
Selling And Marketing Expenses602
Operating Expense47,29424,214
 
Net Interest Income (+$)
Interest Income-
Interest Expense-8,526
Other Finance Cost-8,526
Net Interest Income-
 
Pretax Income (+$)
Operating Income6,146
Net Interest Income-
Other Non-Operating Income Expenses-
Income Before Tax (EBT)1,53210,760
EBIT - interestExpense = -2,380
1,332
3,594
Interest Expense8,526
Earnings Before Interest and Taxes (EBIT)6,14610,058
Earnings Before Interest and Taxes (EBITDA)19,699
 
After tax Income (+$)
Income Before Tax1,532
Tax Provision--
Net Income From Continuing Ops-1,532
Net Income-4,932
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses86,634
Total Other Income/Expenses Net-4,6140
 

Technical Analysis of COSMO Pharmaceuticals SA
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of COSMO Pharmaceuticals SA. The general trend of COSMO Pharmaceuticals SA is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine COSMO Pharmaceuticals SA's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of COSMO Pharmaceuticals SA.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 69.20 < 73.40 < 74.30.

The bearish price targets are: 63.20 > 63.20 > 63.20.

Tweet this
COSMO Pharmaceuticals SA Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of COSMO Pharmaceuticals SA. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

COSMO Pharmaceuticals SA Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of COSMO Pharmaceuticals SA. The current macd is -0.74222785.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the COSMO Pharmaceuticals SA price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for COSMO Pharmaceuticals SA. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the COSMO Pharmaceuticals SA price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
COSMO Pharmaceuticals SA Daily Moving Average Convergence/Divergence (MACD) ChartCOSMO Pharmaceuticals SA Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of COSMO Pharmaceuticals SA. The current adx is 53.91.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy COSMO Pharmaceuticals SA shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
COSMO Pharmaceuticals SA Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of COSMO Pharmaceuticals SA. The current sar is 58.64.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
COSMO Pharmaceuticals SA Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of COSMO Pharmaceuticals SA. The current rsi is 59.55. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
COSMO Pharmaceuticals SA Daily Relative Strength Index (RSI) ChartCOSMO Pharmaceuticals SA Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of COSMO Pharmaceuticals SA. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 5/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the COSMO Pharmaceuticals SA price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
COSMO Pharmaceuticals SA Daily Stochastic Oscillator ChartCOSMO Pharmaceuticals SA Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of COSMO Pharmaceuticals SA. The current cci is 149.32.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
COSMO Pharmaceuticals SA Daily Commodity Channel Index (CCI) ChartCOSMO Pharmaceuticals SA Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of COSMO Pharmaceuticals SA. The current cmo is 41.69.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
COSMO Pharmaceuticals SA Daily Chande Momentum Oscillator (CMO) ChartCOSMO Pharmaceuticals SA Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of COSMO Pharmaceuticals SA. The current willr is -0.73207547.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
COSMO Pharmaceuticals SA Daily Williams %R ChartCOSMO Pharmaceuticals SA Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of COSMO Pharmaceuticals SA.

COSMO Pharmaceuticals SA Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of COSMO Pharmaceuticals SA. The current atr is 0.82503445.

COSMO Pharmaceuticals SA Daily Average True Range (ATR) ChartCOSMO Pharmaceuticals SA Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of COSMO Pharmaceuticals SA. The current obv is -1,883.

COSMO Pharmaceuticals SA Daily On-Balance Volume (OBV) ChartCOSMO Pharmaceuticals SA Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of COSMO Pharmaceuticals SA. The current mfi is 72.74.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
COSMO Pharmaceuticals SA Daily Money Flow Index (MFI) ChartCOSMO Pharmaceuticals SA Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for COSMO Pharmaceuticals SA.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-08-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-14STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-21MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-23STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-27BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-09MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-10STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-22BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-28ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-01ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-03RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-10STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-12-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-18STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-20RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-12-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

COSMO Pharmaceuticals SA Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of COSMO Pharmaceuticals SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.553
Ma 20Greater thanMa 5060.981
Ma 50Greater thanMa 10064.211
Ma 100Greater thanMa 20070.760
OpenGreater thanClose63.200
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of COSMO Pharmaceuticals SA with someone you think should read this too:
  • Are you bullish or bearish on COSMO Pharmaceuticals SA? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about COSMO Pharmaceuticals SA? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about COSMO Pharmaceuticals SA

I send you an email if I find something interesting about COSMO Pharmaceuticals SA.


Comments

How you think about this?

Leave a comment

Stay informed about COSMO Pharmaceuticals SA.

Receive notifications about COSMO Pharmaceuticals SA in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.